Health authorities have officially elevated the public health risk assessment for the ongoing Ebola outbreak in the Democratic Republic of Congo from ‘high’ to ‘very high.’ While the risk remains low on a global scale, the situation in the surrounding African region is currently classified as high, necessitating urgent intervention and heightened surveillance to contain the spread of the virus.

The current outbreak involves the rare Bundibugyo species of Ebola, which lacks a proven vaccine and carries a mortality rate of approximately one-third among those infected. Recent data indicates 177 suspected deaths and 750 suspected cases, with 82 confirmed cases and seven confirmed deaths in the DRC. Neighboring Uganda has also reported two confirmed cases linked to travel from the DRC, though officials describe the situation there as stable.

Efforts to combat the virus are currently underway, with researchers at Oxford University working on a new vaccine candidate utilizing technology similar to that used for the AstraZeneca Covid vaccine. Animal testing is reportedly in progress, with the Serum Institute of India prepared to handle mass production should the vaccine prove effective in upcoming clinical trials. A separate experimental vaccine is also in development, though it is not expected to be ready for testing for several months.

Beyond the medical challenges, the response is being significantly hindered by regional instability and violence. In eastern DRC, public fear and distrust have led to civil unrest, including an incident where a hospital was set on fire following a dispute over burial protocols. Because the bodies of Ebola victims remain highly infectious, authorities are struggling to enforce safe burial practices while simultaneously managing the security of medical personnel working in conflict-affected areas.